Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason J Luke

Showing results (31-40 of 185) with videos related to

Pageof 19
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2024
Unraveling the Therapeutic Benefit of Sequenced Chemo-immunotherapyPaolo D A Vignali, Jason J Luke
Journal for Immunotherapy of Cancer|February 15, 2026
Unlocking the promise of innate biology through the HLA-G/ILT2/ILT4 pathwayCourtney Beers, Robert L Ilaria, Jason J Luke
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2020
PD-1 Blockade in Chinese versus Western Patients with MelanomaAlexander N Shoushtari, Riyue Bao, Jason J Luke
Journal for Immunotherapy of Cancer|February 7, 2023
Targeting Cbl-b in cancer immunotherapyRyan C Augustin, Riyue Bao, Jason J Luke
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2018
Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon AxisBrian W Labadie, Riyue Bao, Jason J Luke
Frontiers in Oncology|June 28, 2021
Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted ImmunotherapyClaudia Trojaniello, Jason J Luke, Paolo A Ascierto
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2022
Old Dog, New Trick: A Tumor-Intrinsic Role for PD-1 in Chemoresistant Tumor SubclonesRyan C Augustin, Riyue Bao, Jason J Luke
Health Affairs (Project Hope)|March 9, 2011
Episode-based payment for cancer care: a proposed pilot for MedicarePeter B Bach, Joshua N Mirkin, Jason J Luke
Cancers|November 13, 2021
Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and BiomarkersBrian W Labadie, Arjun V Balar, Jason J Luke
Drugs|November 22, 2014
The biology and clinical development of MEK inhibitors for cancerJason J Luke, Patrick A Ott, Geoffrey I Shapiro
Pageof 19

Showing results (31-40 of 185) with videos related to

Sort By:
Pageof 19
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2024
Unraveling the Therapeutic Benefit of Sequenced Chemo-immunotherapyPaolo D A Vignali, Jason J Luke
Journal for Immunotherapy of Cancer|February 15, 2026
Unlocking the promise of innate biology through the HLA-G/ILT2/ILT4 pathwayCourtney Beers, Robert L Ilaria, Jason J Luke
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2020
PD-1 Blockade in Chinese versus Western Patients with MelanomaAlexander N Shoushtari, Riyue Bao, Jason J Luke
Journal for Immunotherapy of Cancer|February 7, 2023
Targeting Cbl-b in cancer immunotherapyRyan C Augustin, Riyue Bao, Jason J Luke
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2018
Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon AxisBrian W Labadie, Riyue Bao, Jason J Luke
Frontiers in Oncology|June 28, 2021
Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted ImmunotherapyClaudia Trojaniello, Jason J Luke, Paolo A Ascierto
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2022
Old Dog, New Trick: A Tumor-Intrinsic Role for PD-1 in Chemoresistant Tumor SubclonesRyan C Augustin, Riyue Bao, Jason J Luke
Health Affairs (Project Hope)|March 9, 2011
Episode-based payment for cancer care: a proposed pilot for MedicarePeter B Bach, Joshua N Mirkin, Jason J Luke
Cancers|November 13, 2021
Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and BiomarkersBrian W Labadie, Arjun V Balar, Jason J Luke
Drugs|November 22, 2014
The biology and clinical development of MEK inhibitors for cancerJason J Luke, Patrick A Ott, Geoffrey I Shapiro
Pageof 19